1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
North America Cancer Tissue Diagnostics Market to 2027 - Regional Analysis and Forecasts by Test Type and Country

North America Cancer Tissue Diagnostics Market to 2027 - Regional Analysis and Forecasts by Test Type and Country

  • August 2019
  • 132 pages
  • ID: 5815414
  • Format: PDF
  • The Insight Partners
Up to $1000 off Until Jun 20th 2021


Table of Contents

Search Inside

The North America cancer tissue diagnostics market is expected to reach US$ 1,587.38 Mn in 2027 from US$ 923.79 Mn in 2018. This market is projected to grow at a growth rate of 6.5% from 2019-2027.
The growth of the cancer tissue diagnostics market is primarily attributed to growing cancer prevalence in North American region and new product launches & FDA approvals.However, lack of reimbursement policies for cancer diagnosis is likely to pose a negative impact on the market growth.

On the other hand, growing medical tourism in Mexico is likely to have a positive impact on the growth of the North America cancer tissue diagnostics market in the coming years.
Personalize medicine is a new approach relatively and is expanding significantly in the healthcare sector.It enables a medical practitioner to select treatment based on a patient’s genetic profile.

This approach not only minimizes harmful side effects but also leads to successful result within a short period.Cancer personalize medicine involves the study of individuals genetic makes up for tumor growth.

By studying the patient’s genetic make-up, an oncologist may customize the treatment depending on the patient’s genetic mutations.In the US, attempts are made to integrate personalized medicine into healthcare practices.

In the United States, The Precision Medicine Initiative (PMI) is a research endeavor, which involves the National Institutes of Health (NIH) and various other research centers. The initiative has been created to analyze a person’s genetics, environment, and lifestyle to determine a suitable approach for the prevention or treatment of disease. The PMI was launched during the fiscal year 2016, approximately $130 million were allocated to NIH to establish a large-scale research participant group, called a cohort. Nearly $70 million was given to the National Cancer Institute to conduct studies in cancer genomics as part of PMI for Oncology. These initiatives are expected to increase awareness regarding personalized medicine during the forecast period.
Moreover, the companies namely, Agilent Technologies Inc., Thermo Fisher Scientific, Inc., Cancer Genetics Inc. and F. Hoffmann-La Roche Ltd. have received approvals in the cancer tissue diagnostics market. Some of the recent approvals are mentioned below.
Table 1. Recent Approvals For Cancer Tissue Diagnostics in the Market
Month & Year Company Description
June, 2019 Agilent Technologies Inc. Agilent Technologies Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-L1 IHC 22C3 pharmDx assay. The assay is approved to aim in identifying patients with head and neck squamous cell carcinoma (HNSCC) for treatment with KEYTRUDA (pembrolizumab), anti-PD-1 therapy manufactured by Merck.
October, 2018 Thermo Fisher Scientific, Inc.Thermo Fisher Scientific received CE mark for its Oncomine Dx Target Test.

The approval has enabled the company to offer NGS testing and precision oncology across the globe.
April, 2018 Cancer Genetics Inc. Cancer Genetics, Inc. received special 510(k) approval from the FDA for its Tissue of Origin test (TOO) that follows modifications made to test reagents and software.
June, 2017 F.Hoffmann-La Roche Ltd.

Roche received approval for the VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer.
August, 2016 Agilent Technologies Inc.Dako, Agilent received the CE mark for cancer therapy.

The new companion diagnostic assay reveals that the patient with advanced non-small cell lung cancer (NSCLC) will respond to KEYTRUDA(r) (pembrolizumab), an anti-PD-1 therapy.

In 2018, the immunohistochemical tests segment held a largest market share of 57.84% of the cancer tissue diagnostics market, by test type. This segment is also expected to dominate the market in 2027 owing to the low cost of the procedure. Higher acceptance of the method for diagnosis purpose. Moreover, the technique is easily accessible, and growth in number of products based on technology. Additionally, the rising prevalence of cancer is a major factor for the growth of the diagnostic tests.
Some of the major primary and secondary sources for cancer tissue diagnostics included in the report are, World Health Organization (WHO), Canadian Institutes of Health Research (CIHR), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), and National Institute for Health among others.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
20% Off


  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

North America Irritable Bowel Syndrome Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Diagnosis, and Indication

  • $ 3000
  • May 2021
  • 109 pages

The North America irritable bowel syndrome (IBS) diagnostics market is expected to reach US$ 1,529.08 million by 2028 from US$ 950.83 million in 2020; it is estimated to grow at a CAGR of 6.2% from 2021 ...

  • United States
  • North America
  • Gastrointestinal Drug
  • Digestive System Disorder
  • Industry analysis
  • Drug Approval
  • Diagnostic Revenue


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on